Nicotinamide Riboside

The NAD⁺ Salvage Pathway#

NR is a vitamin B3 analog that enters cells and gets phosphorylated by nicotinamide riboside kinases (NRK1/NRK2) to nicotinamide mononucleotide (NMN), which is then converted to NAD⁺ by NMNAT enzymes. This is a dedicated two-step route — faster and more efficient than the de novo tryptophan pathway, and it bypasses the rate-limiting step that throttles niacin and nicotinamide. A portion of oral NR is also cleaved to nicotinamide by gut and hepatic enzymes before re-entering the salvage cycle, which is why the NAM and NAAD arms of the NAD⁺ metabolome both rise after dosing.

The practical result: NR roughly doubles whole-blood NAD⁺ within 2–8 weeks of daily dosing, and that elevation is sustained across 24 hours on once-daily administration.

"NR is orally available in both mice and humans, increases NAD⁺ and its metabolites in a dose-dependent manner, and exhibits a favorable pharmacokinetic profile for once-daily administration." — Trammell SAJ et al., Nature Communications (2016)

Sirtuin Activation#

NAD⁺ is the obligate cofactor for the sirtuin family (SIRT1, SIRT3, SIRT6) — deacetylases that regulate mitochondrial biogenesis, fatty-acid oxidation, DNA repair, and stress resistance. When NAD⁺ is abundant, sirtuins run; when it's depleted (aging, metabolic stress, alcohol, oral steroids), they stall. Raising NAD⁺ via NR is the upstream lever that lets sirtuin-activating compounds like pterostilbene and resveratrol actually do their job, which is why the two are almost always stacked together.

This sirtuin axis is the backbone of NR's longevity pitch: better mitochondrial quality control, improved lipid handling in liver tissue, and stronger DNA damage response under oxidative load.

PARP and CD38 Buffering#

Two enzyme systems consume NAD⁺ aggressively: PARPs (activated by DNA damage) and CD38 (an ectoenzyme that climbs steadily with age and inflammation). By the time you're 60, CD38 activity alone can cut tissue NAD⁺ roughly in half. NR supplementation doesn't inhibit these consumers — it just keeps the substrate pool full enough that sirtuins and other NAD⁺-dependent processes aren't starved out. Think of it as topping up a tank that age, cycle stress, and inflammation are constantly draining.

Hepatic and Vascular Effects#

NR distributes readily to liver and vascular tissue, which is where most of its demonstrated human benefit lives. Hepatic NAD⁺ elevation supports mitochondrial β-oxidation and liver regeneration — the mechanistic basis for running NR alongside TUDCA and NAC during or after oral cycles. In the vasculature, restored NAD⁺ improves endothelial function and aortic compliance, which translates to a measurable drop in systolic blood pressure in hypertensive adults.

"Daily supplementation with 500 mg NR for six weeks elevated NAD⁺ by approximately twofold in healthy middle-aged and older adults. Systolic blood pressure was reduced by about 8 mmHg in those with stage-1 hypertension." — Martens CR et al., Nature Communications (2018)

For anyone watching BP drift on cycle, that's a real, replicated ~8 mmHg adjunct — not a replacement for telmisartan or a proper AI protocol, but a legitimate supporting mechanism.

The Skeletal Muscle Blind Spot#

Here's where the honest picture matters: NR does not meaningfully raise NAD⁺ in human skeletal muscle at oral doses, and even when muscle NAD⁺ is forced up via IV administration, mitochondrial respiration and insulin sensitivity don't move.

"Oral NR supplementation in older adults raised the skeletal muscle NAD⁺ metabolome, but did not improve mitochondrial respiratory function, muscle strength, or whole-body metabolism." — Elhassan YS et al., Cell Reports (2019)

"Despite marked elevations in skeletal muscle NAD⁺ with intravenous NR, there was no meaningful effect on mitochondrial function or insulin sensitivity." — Damgaard MV et al., iScience (2022)

This is the single most important mechanistic caveat for a physique-focused reader: NR is a systemic, liver, and vascular compound, not a performance or recomp tool. Buy it for NAD⁺ restoration, cycle-support hepatics, and long-term cardiovascular endpoints — and stack pterostilbene or resveratrol on top if you want the sirtuin pathway fully lit. Don't buy it expecting a training effect.

Common (most users)#

• Mild GI upset, nausea, or bloating — most often at ≥1 g/day, usually in the first 1–2 weeks. Take with a full breakfast; split the dose AM and early afternoon if it persists.
• Headache or transient fatigue — reported in a small minority across trials, typically self-limiting within a week. Check hydration and magnesium intake before assuming it's the NR.
• Skin flushing — genuinely rare with NR (unlike nicotinic acid, NR doesn't meaningfully hit GPR109A acutely). If you're flushing, you likely bought a product that's degraded to nicotinamide/niacin — check the powder color and source.

"NR at doses up to 2000 mg/day for 12 weeks was safe and well-tolerated, with adverse events comparable to placebo and no significant effects on hepatic, renal, or cardiovascular markers." — Conze, Brenner & Kruger, Scientific Reports (2019)

Uncommon (dose-dependent or individual)#

• Methyl-donor drain / rising homocysteine — NAD⁺ turnover consumes SAMe via NNMT. At chronic doses ≥1 g/day this can nudge homocysteine up in susceptible users. Add 1–2 g TMG (betaine) daily, ensure adequate B12 and folate, and recheck homocysteine at 8–12 weeks.
• Mild muscle soreness or "off" days — reported in small numbers in the Elhassan cohort. Usually resolves without intervention; if it doesn't, drop back to 300–500 mg.
• Sleep disturbance with late dosing — some users find evening dosing activating. Keep it to breakfast or split AM/early-afternoon.
• No meaningful hepatic, renal, glucose, or lipid shifts across the 300–2000 mg range in published trials — bloodwork stays clean. If your panel moves, look to the rest of your stack first.

Rare but serious#

• Theoretical oncology signal — preclinical data (mouse TNBC brain-metastasis model) suggest that NAD⁺ precursors may feed metabolically demanding tumors. No human signal has emerged, but this is the one pharmacologically plausible concern and worth flagging.
• Severe GI intolerance — very rare. Persistent vomiting or diarrhea at standard doses is not an NR pattern; investigate the product (degraded bulk NR, contaminated capsule) before blaming the molecule.

Hard contraindications#

• Active malignancy — defer NR until the human oncology data matures. Do not run a NAD⁺ precursor alongside active cancer treatment without oncology input.
• Pregnancy and lactation — not studied. No human safety data. Do not use.
• Confirmed degraded product — if bulk NR powder is yellow or brown instead of off-white, bin it. You are dosing mostly nicotinamide at that point, and at high mg loads nicotinamide has its own hepatotoxicity ceiling that NR doesn't.

Sex-specific considerations and PCT#

NR is non-hormonal. No virilization risk, no HPG-axis suppression, no effect on menstrual cycle, no impact on semen parameters, and no PCT requirement — it stacks cleanly alongside AAS, SARMs, or any peptide protocol without interfering with recovery. Dosing is identical for men and women; there's no rationale for sex-specific adjustment. For anyone pregnant, attempting conception, or breastfeeding, the answer is simply not yet — the molecule hasn't been studied in those populations and there's no reason to be the test case.